Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bristol Myers CEO sees mid-decade transition, late decade growth
February 2, 2024 7:04 AM ESTBy Michael Erman
(Reuters) -Bristol Myers Squibb's new chief executive said on Friday that the company was focused on driving growth toward the end of the decade but would first need to weather a difficult transition period beginning in 2026.
Bristol shares were up about half a percent in early trading.
Chris Boerner took over as CEO in November right after the company pared back expectations for its existing new product portfolio.
The company is expecting its top selling drugs, blood thinner Eliquis and cancer immunotherapy Opdivo, to lose patent protection later this decade. It... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c, offers guidance
February 2, 2024 7:01 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.70, $0.10 better than the analyst estimate of $1.60. Revenue for the quarter came in at $11.48 billion versus the consensus estimate of $11.22 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2024 EPS of $7.10-$7.40, versus the consensus of $7.39.... More
